ACA
MRTX

Avoro Capital Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Avoro Capital Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,886,840
Closed -$287M – 53
2023
Q4 		$287M Sell
4,886,840
-1,779,826
-27% -$100M 3.97% 12
2023
Q3 		$290M Buy
6,666,666
+1,111,111
+20% +$39.7M 4.53% 11
2023
Q2 		$201M Hold
5,555,555
– – 2.72% 14
2023
Q1 		$207M Hold
5,555,555
– – 3.06% 12
2022
Q4 		$252M Buy
5,555,555
+5,000
+0.1% +$324K 3.76% 11
2022
Q3 		$388M Hold
5,550,555
– – 7.16% 4
2022
Q2 		$373M Buy
5,550,555
+225,555
+4% +$14.3M 7.36% 5
2022
Q1 		$438M Buy
5,325,000
+250,000
+5% +$25.6M 7.99% 4
2021
Q4 		$744M Buy
5,075,000
+75,000
+2% +$11.6M 12.67% 2
2021
Q3 		$885M Hold
5,000,000
– – 13.89% 2
2021
Q2 		$808M Buy
5,000,000
+325,000
+7% +$52.2M 14.05% 2
2021
Q1 		$801M Buy
4,675,000
+140,000
+3% +$27.7M 13.83% 2
2020
Q4 		$996M Buy
4,535,000
+192,000
+4% +$41.5M 17.15% 1
2020
Q3 		$721M Buy
4,343,000
+56,235
+1% +$7.7M 10.25% 2
2020
Q2 		$489M Buy
4,286,765
+174,065
+4% +$16.9M 9.68% 2
2020
Q1 		$316M Buy
4,112,700
+262,500
+7% +$23.5M 10.67% 2
2019
Q4 		$496M Buy
3,850,200
+100,200
+3% +$9.66M 14.57% 2
2019
Q3 		$292M Sell
3,750,000
-112,500
-3% -$10.6M 12.19% 1
2019
Q2 		$398M Hold
3,862,500
– – 13.75% 1
2019
Q1 		$283M Sell
3,862,500
-935,601
-19% -$63.6M 12.24% 2
2018
Q4 		$204M Hold
4,798,101
– – 12.17% 2
2018
Q3 		$226M Hold
4,798,101
– – 10.38% 2
2018
Q2 		$237M Buy
4,798,101
+400,000
+9% +$15.1M 9.11% 2
2018
Q1 		$135M Hold
4,398,101
– – 6.45% 5
2017
Q4 		$80.3M Buy
4,398,101
+687,500
+19% +$10.7M 5.2% 4
2017
Q3 		$43.4M Buy
3,710,601
+1,435,200
+63% +$8.3M 3.37% 11
2017
Q2 		$8.3M Sell
2,275,401
-107,800
-5% -$413K 1.05% 24
2017
Q1 		$12.4M Buy
2,383,201
+875,000
+58% +$4.8M 1.58% 22
2016
Q4 		$7.16M Buy
1,508,201
+19,714
+1% +$107K 1.45% 21
2016
Q3 		$9.84M Buy
1,488,487
+273,654
+23% +$1.46M 1.73% 19
2016
Q2 		$6.63M Sell
1,214,833
-189,222
-13% -$3.02M 1.47% 21
2016
Q1 		$30M Buy
1,404,055
+146,000
+12% +$3.26M 10.48% 1
2015
Q4 		$39.8M Sell
1,258,055
-195,000
-13% -$6.89M 13.69% 1
2015
Q3 		$50M Buy
1,453,055
+453,055
+45% +$13.7M 13% 2
2015
Q2 		$31.5M Buy
1,000,000
+679,133
+212% +$20M 8.67% 3
2015
Q1 		$9.41M Buy
+320,867
New +$7.53M 3.61% 9

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Avoro Capital Advisors's MRTX Position: Q1 2024 in Review

Avoro Capital Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 4,886,840 shares — an estimated $287M sold.

Avoro Capital Advisors first reported a position in MRTX in Q1 2015 and held it in 36 quarters. The position peaked at $996M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Avoro Capital Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Avoro Capital Advisors sold 4,886,840 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $287M.
  • Avoro Capital Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 36 quarters.
  • Avoro Capital Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $996M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Avoro Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.